Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLife Science Regulatory News (LABS)

  • This share is currently suspended. It was suspended at a price of 43.10
  • There is currently no data for LABS

Form 8.3

5 Feb 2026 10:54

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:

NATIXIS SA

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Life Science REIT plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

04 February 2026

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

Yes - British Land Company plc

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

1p ordinary

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

2 225 774

0,63

-

0,00

(2) Cash-settled derivatives:

-

0,00

2 225 774

0,63

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

TOTAL:

2 225 774

0,63

2 225 774

0,63

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

1p ordinary

Purchase

470 000

GBX 43.62

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e,g, CFD

Nature of dealing

e,g, opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

1p ordinary

TRS

Increasing a short position

470 000

GBX 43.62

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e,g, call option

Writing, purchasing, selling, varying etc,

Number of securities to which option relates

Exercise price per unit

Type

e,g, American, European etc,

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description

e,g, call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e,g, subscription, conversion

Details

Price per unit (if applicable)

4, OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included, If there are no such agreements, arrangements or understandings, state “none”

NONE

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

NONE

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:

05 February 2026

Contact name:

Florence de Queylar

Telephone number*:

+33 1 58 19 40 93

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service,

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129,

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel’s Market Surveillance Unit,

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk

View source version on businesswire.com: https://www.businesswire.com/news/home/20260205364381/en/

Copyright Business Wire 2026

Date   Source Headline
26th Jun 202510:09 amRNSForm 8.5 (EPT/RI)
25th Jun 20252:30 pmGNWForm 8.3 - Life Science REIT Plc
25th Jun 202511:30 amRNSForm 8.3 - Life Science REIT PLC
25th Jun 202510:47 amRNSForm 8.5 (EPT/RI)
24th Jun 20254:56 pmRNSForm 8.3 - Life Science
24th Jun 20253:20 pmRNSForm 8.3 - Life Science REIT plc
24th Jun 20252:47 pmRNSForm 8.3 - Life Science REIT plc
24th Jun 20252:45 pmGNWForm 8.3 - Life Science REIT Plc
24th Jun 202512:18 pmRNSForm 8.3 - Life Science REIT plc
24th Jun 202510:11 amRNSForm 8.5 (EPT/RI)
23rd Jun 20253:25 pmBUSForm 8.3 - Life Science REIT plc
23rd Jun 20253:20 pmRNSForm 8.3 - Life Science REIT plc
23rd Jun 20252:43 pmGNWForm 8.3 - Life Science REIT Plc
23rd Jun 20252:23 pmRNSForm 8.3 - Life Science REIT plc
23rd Jun 202510:36 amRNSForm 8.5 (EPT/RI)
23rd Jun 20258:14 amRNSForm 8.3 - LIFE SCIENCE REIT PLC
20th Jun 20251:41 pmGNWForm 8.3 - Life Science REIT Plc
20th Jun 202512:29 pmRNSForm 8.3 - Life Science REIT plc
20th Jun 202510:15 amRNSForm 8.5 (EPT/RI)
20th Jun 20259:56 amRNSForm 8.3 - Life Science REIT plc
20th Jun 20259:17 amRNSForm 8.3 - Life Science REIT plc
20th Jun 20259:17 amRNSForm 8.3 - Life Science REIT plc
19th Jun 20254:41 pmRNSForm 8.3 - Life Science
19th Jun 20253:27 pmRNSForm 8.3 - Life Science REIT plc
19th Jun 20253:20 pmRNSForm 8.3 - Life Science REIT plc
19th Jun 20252:24 pmGNWForm 8.3 - Life Science REIT Plc
19th Jun 202511:15 amRNSForm 8.5 (EPT/RI)
18th Jun 20255:20 pmRNSHolding(s) in Company
18th Jun 20253:20 pmRNSForm 8.3 - Life Science REIT plc
18th Jun 20253:03 pmGNWForm 8.3 - Life Science REIT Plc
18th Jun 202510:42 amRNSForm 8.5 (EPT/RI)
17th Jun 20254:28 pmRNSForm 8.3 - Life Science
17th Jun 20253:20 pmRNSForm 8.3 - Life Science REIT plc
17th Jun 202510:49 amRNSForm 8.5 (EPT/RI)
16th Jun 20251:39 pmRNSForm 8.3 - Life Science REIT plc
16th Jun 202511:04 amRNSForm 8.5 (EPT/RI)
13th Jun 202512:49 pmRNSForm 8.3 - Life Science REIT plc
13th Jun 20259:52 amRNSForm 8.5 (EPT/RI)
12th Jun 20254:32 pmRNSForm 8.3 - Life Science
12th Jun 20251:46 pmGNWForm 8.3 - Life Science REIT Plc
12th Jun 202510:40 amRNSForm 8.5 (EPT/RI)
11th Jun 20255:14 pmRNSForm 8.3 - Life Science REIT plc
11th Jun 20253:20 pmRNSForm 8.3 - Life Science REIT plc
11th Jun 20252:56 pmGNWForm 8.3 - Life Science REIT Plc
11th Jun 202510:28 amRNSForm 8.5 (EPT/RI)
11th Jun 20258:07 amRNSForm 8.3 - Life Science REIT plc
10th Jun 20252:52 pmGNWForm 8.3 - Life Science REIT Plc
10th Jun 20251:52 pmRNSForm 8.3 - Life Science REIT plc
10th Jun 202510:38 amRNSForm 8.3 - Life Science REIT PLC
10th Jun 202510:12 amRNSForm 8.3 - Life Science REIT plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.